Shifting Back

Coombs, Amy
May 2007
Red Herring;5/28/2007, Vol. 4 Issue 17/18, p12
Trade Publication
The article discusses the possible growth in investment in early-stage pharmaceutical development, according to venture capitalists. As pre-clinical and early-clinical companies able to raise money have seen less competition and also have become more attractive acquisition targets, investors are seeing higher returns than ever before. The average value of early-stage companies tripled in just two years, jumping from $4 million in 2004 to $12 million in 2006, according to a Thomson Financial report. And in the three-year period from 2003 to 2005, the average value of licensing and partnering deals between pre-clinical projects and large pharmaceutical companies spiked to $77 million, more than twice the value in the late 1990s, according to Recombinant Capital.


Related Articles

  • VC Funding Rises to Pre-Crash Levels. Salamone, Salvatore // Bio-IT World;May2005, Vol. 4 Issue 5, p14 

    Reports on the returns of venture capital funding to pre-cash levels in the U.S. in 2005. Existence of a funding gap on the capital funding; Views of Matthew McCooe, director of new ventures at the Columbia University Science and Technology Ventures in New York, on investors; Involvement of...

  • Secret Key to the heart of Venture Capitalists. Sahu, Anamika // Siliconindia;Oct2014, p22 

    The article offers the author's insights on venture capital (VC) in India. Topics discussed by the author include how VC companies invest in companies that can provide unique ideas and profound integration of social, customer, and interesting usability, the commitment of companies towards...

  • National Venture Capital Surge Includes Michigan. Hoekman, David // Grand Rapids Business Journal;10/09/2000, Vol. 18 Issue 41, pB6 

    Reports on the flourishing of venture capital in Michigan as of October 2000. Improvement of access of state-based growth-oriented firms to private venture capital; Average amount of investment returns expected by the venture capital community.

  • A New Model for VC Funding? Paul Capital Bets $100M on It. Moran, Nuala // BioWorld International;1/13/2010, Vol. 15 Issue 2, p3 

    The article focuses on the decision of Paul Capital to provide roughly 100 million U.S. dollars to a new European company established to fund and conduct Phase III trials. It is noted that the move by the health care investor benefits companies that lack resources to advance products. The new...

  • Explaining entrepreneurial finance. Oliver, Leith // NZ Business;Feb2011, Vol. 25 Issue 1, p52 

    The article explains entrepreneurial finance which is inimical to start-up businesses seeking funds from angel investors. Potential business owners are advised to analyze the risks associated with achieving the required rates of return (ROR) at every step of developing the business. Investors...

  • The Missing Preferred Return. Fleischer, Victor // Journal of Corporation Law;Fall2005, Vol. 31 Issue 1, p77 

    The article talks about the missing preferred return on the part of venture capitalists (VCs). VCs take their cut from the first dollar of nominal profits and offer no preferred return unlike what managers of buyout funds do. The missing preferred return is puzzling because it suggests that VCs...

  • Are you investment ready? Watt, Amanda // NZ Business;Sep2009, Vol. 23 Issue 8, p58 

    The article provides steps on how to attract more investors for businesses. A venture capital is defined as being investors or fund managers who pay cash in return for part ownership of the shares in a company. It states that potential return on investment, financial projections, and competitive...

  • Venture capital on a shoestring: Bioventures'pioneering life sciences fund in South Africa. Masum, Hassan; Singer, Peter A. // BMC International Health & Human Rights;Jan2010 Supplement 1, Vol. 10, p1 

    Background: Since 2000, R&D financing for global health has increased significantly, with innovative proposals for further increases. However, although venture capital (VC) funding has fostered life sciences businesses across the developed world, its application in the developing world and...

  • How VCs Think. McGinn, Daniel // Inc.;Nov2012, Vol. 34 Issue 9, p28 

    The article discusses the results of a research study on the factors affecting the decision making of venture capitalists. The study revealed the key factor focused on the deal's fundamentals which include the potential return and the companies' readiness to market environment. About 4.6 percent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics